HOMBACH ROBERT J. 4
4 · Seaport Therapeutics, Inc. · Filed Jun 24, 2026
Research Summary
AI-generated summary of this filing
Seaport Therapeutics (SPTX) Director Robert Hombach Buys 13,000 Shares
What Happened
- Robert J. Hombach, a director of Seaport Therapeutics (SPTX), acquired 13,000 shares on 2026-06-22 in an open-market purchase (transaction code P). The reported weighted average price was $18.14 per share, for a total reported cost of $235,768. This was a purchase rather than a sale.
Key Details
- Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (timely filing).
- Price: weighted average $18.14; reported purchase price range $17.65–$18.27 (per footnote).
- Shares acquired: 13,000; total value reported: $235,768.
- Shares owned after transaction: not disclosed in the provided Form 4 excerpt.
- Footnotes: F1 notes the weighted-average price and the underlying per-share price range; F2 states the reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
- No indication of a 10b5-1 plan, tax withholding, gift, or derivative exercise in this filing.
Context
- Insider purchases are often noted by investors as a potential signal of confidence, but they are one data point and not a guarantee of future stock performance. This filing documents a straightforward open-market purchase by a company director and was filed promptly with the SEC.
Insider Transaction Report
Form 4
HOMBACH ROBERT J.
Director
Transactions
- Purchase
Common Stock
[F1][F2]2026-06-22$18.14/sh+13,000$235,768→ 13,000 total(indirect: By Trust)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.65 to $18.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Signature
/s/ Lana Gladstein, Attorney-in-Fact|2026-06-24